NCT04522544 2026-02-18
Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Recruiting
Clinical Trials
20 trialsNCT06904170 2026-02-03
ALICE
UNICANCER
Phase 2/3 Recruiting
NCT06921785 2026-01-09
ARTEMIDE-HCC01
AstraZeneca
Phase 3 Recruiting
NCT06526104 2026-01-06
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT07081633 2025-12-30
TREMENDOUS-2
AstraZeneca
Phase 2 Recruiting
NCT06880523 2025-12-18
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT04430452 2025-12-08
Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma
University of California, San Francisco
Phase 2 Recruiting
NCT06698250 2025-11-06
ZENOBIA
University of Pittsburgh
Phase 2 Recruiting
NCT06999694 2025-09-10
Proton-STRIDE
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT05701488 2025-09-02
SIRT With Tremelimumab and Durvalumab for Resectable HCC
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT06109272 2025-08-15
LIVIGNO-2
AbbVie
Phase 2/3 Recruiting
NCT06999707 2025-06-05
Photon-STRIDE
Chang Gung Memorial Hospital
Phase 2 Recruiting
NCT06911255 2025-05-14
Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma
Seoul National University Hospital
Phase 1/2 Recruiting
NCT06045975 2025-04-02
DUMELEP
Assistance Publique - Hôpitaux de Paris
Phase 2 Recruiting
NCT06710223 2025-02-11
Cryoablation and Arterial Infusion of SD-101 in Combination with Durvalumab and Tremelimumab
University of California, San Diego
Phase 1 Recruiting
NCT05557838 2025-02-07
TREMENDOUS
AstraZeneca
Phase 3 Recruiting
NCT05844046 2024-07-16
MONTBLANC
Ludwig-Maximilians - University of Munich
Phase 2 Recruiting
NCT04988945 2023-09-06
TACE and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular Carcinoma
The University of Hong Kong
Phase 2 Recruiting
NCT05809869 2023-04-12
Immunotherapy and Radioembolisation for Metastatic Hepatocellular Carcinoma
The University of Hong Kong
Phase 2 Recruiting
NCT03482102 2022-09-08
Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer
Massachusetts General Hospital
Phase 2 Recruiting